LGALS8 and central nervous system cancer: The cross-validation results demonstrated that GAL-8 had a strong discriminatory power between glioma patients and healthy controls with an accuracy rate of 76.7%, and a moderate ability to differentiate between HGG and LGG with an accuracy rate of 68.0%.